Acadian Asset Management
ATXS

Acadian Asset Management’s Astria Therapeutics ATXS Stock Holding History

Acadian Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,411
Closed -$26K – 1640
2024
Q3 		$26K Buy
+2,411
New +$26.8K ﹤0.01% 1935
2023
Q1 		– Sell
-23,429
Closed -$348K – 1740
2022
Q4 		$348K Buy
23,429
+11,968
+104% +$123K ﹤0.01% 1138
2022
Q3 		$103K Buy
+11,461
New +$76.8K ﹤0.01% 1355
2021
Q1 		– Sell
-1,960
Closed -$25K – 2053
2020
Q4 		$25K Buy
+1,960
New +$34.9K ﹤0.01% 2108
2019
Q2 		– Sell
-487
Closed -$23K – 1785
2019
Q1 		$23K Buy
+487
New +$16.5K ﹤0.01% 1796
2018
Q1 		– Sell
-272
Closed -$24K – 1675
2017
Q4 		$24K Buy
+272
New +$32K ﹤0.01% 1340
2017
Q3 		– Sell
-254
Closed -$21K – 1401
2017
Q2 		$21K Buy
+254
New +$21.1K ﹤0.01% 1245

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Acadian Asset Management's ATXS Position: Q4 2024 in Review

Acadian Asset Management sold out of Astria Therapeutics (ATXS) in Q4 2024, closing a stake of 2,411 shares — an estimated $26K sold.

Acadian Asset Management first reported a position in ATXS in Q2 2017 and held it in 7 quarters. The position peaked at $348K in Q4 2022. 110 funds tracked by Wall St. Rank hold ATXS as of Q4 2024.

  • Acadian Asset Management reported no remaining Astria Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 2,411 Astria Therapeutics shares in Q4 2024, an estimated $26K.
  • Acadian Asset Management first reported a position in Astria Therapeutics in Q2 2017 and held it in 7 quarters.
  • Acadian Asset Management's Astria Therapeutics position peaked at $348K in Q4 2022.
  • 110 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.